Details of the Drug Combination

General Information of Drug Combination (ID: DCS4T2R)

Drug Combination Name
MK-4815 SB-612111
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs MK-4815   DMT9K74 SB-612111   DM2SZ3F
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 4.415
Bliss Independence Score: 5.303
Loewe Additivity Score: 0.221
LHighest Single Agent (HSA) Score: 1.009

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-4815
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Investigative [2]
Indication(s) of SB-612111
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Investigative [3]
SB-612111 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Nociceptin receptor (OPRL1) TTNT7K8 OPRX_HUMAN Antagonist [4]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1693).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320).